Chronic lymphocytic leukemia (CLL) is a slow-growing cancer of B lymphocytes that mostly affects older adults, and for many people it is a long-term condition rather than an immediate threat. Its causes are not fully known, but family history and age are the strongest risk factors. Many patients need no treatment for years, and when treatment is needed, modern targeted drugs taken by mouth control the disease well for most. Survival depends heavily on stage, genetic features of the leukemia cells, and overall health.
CLL is the most common leukemia in adults in Western countries, and it is one of the conditions I discuss most often in hematology clinic. Below I cover what it is, why it happens, how it is diagnosed and staged, how it is treated, and what really drives outlook.
What Is Chronic Lymphocytic Leukemia?
CLL begins in the bone marrow, where a single B lymphocyte acquires changes that let it survive far longer than it should. B lymphocytes are white blood cells that normally make antibodies. In CLL, mature-looking but dysfunctional B cells slowly accumulate in the blood, marrow, lymph nodes, and spleen.
Unlike acute leukemias, which progress over days to weeks, CLL usually evolves over years. The median age at diagnosis is around 70, and it is uncommon before 40. It is slightly more common in men.
A closely related condition, small lymphocytic lymphoma (SLL), involves the same cells but located mainly in the lymph nodes rather than the blood. It is treated the same way.
Causes and Risk Factors
There is no single known cause of CLL. It arises from acquired genetic changes in B cells, not usually from an inherited gene passed from parent to child. Recognized risk factors include:
- Age: risk rises steadily after 50.
- Family history: having a first-degree relative with CLL or another lymphoid cancer raises risk several-fold, although the absolute risk stays low.
- Sex: men are affected more often than women.
- Chemical exposure: some herbicides and pesticides, including Agent Orange, have been linked to CLL.
Many healthy older adults have a small population of CLL-type cells in their blood without any illness. This is called monoclonal B-cell lymphocytosis (MBL), and only a small minority progress to CLL each year.
Inside the cancer cells, certain genetic changes matter a great deal. Loss of part of chromosome 17 (del(17p)) or mutation of the TP53 gene, loss of part of chromosome 11 (del(11q), which includes the ATM gene), and whether the IGHV genes are mutated all influence how the disease behaves and which treatments work best.
Signs, Symptoms, and Diagnosis
Many people have no symptoms and are diagnosed after a routine blood test shows a high lymphocyte count. When symptoms occur, they include painless swollen lymph nodes, fatigue, a feeling of fullness under the left ribs from an enlarged spleen, and frequent infections. Some develop “B symptoms”: fevers, drenching night sweats, and unintentional weight loss.
Diagnosis rests on three tests:
- Complete blood count showing at least 5,000 clonal B cells per microliter of blood (5 x 10^9/L), the standard diagnostic threshold.
- Blood smear showing small mature lymphocytes and fragile “smudge cells.”
- Flow cytometry confirming the characteristic marker pattern, including CD5 and CD23 on B cells.
Before treatment, doctors add FISH testing for chromosome changes, TP53 mutation analysis, and IGHV status. A bone marrow biopsy is not always needed but helps when blood counts are unexplained.
Staging CLL
Two staging systems are used worldwide. Both rely on a physical exam and blood count rather than scans.
| Rai stage | Findings | Risk group |
|---|---|---|
| 0 | Lymphocytosis only | Low |
| I | Lymphocytosis plus enlarged lymph nodes | Intermediate |
| II | Lymphocytosis plus enlarged spleen or liver | Intermediate |
| III | Lymphocytosis plus anemia (hemoglobin below 11 g/dL) | High |
| IV | Lymphocytosis plus low platelets (below 100,000 per microliter) | High |
The Binet system, used more in Europe, groups patients into stages A, B, and C based on the number of enlarged lymphoid areas and the presence of anemia or low platelets.
Treatment Options
Early-stage CLL without symptoms is usually managed with “watch and wait” (active monitoring). Treating early disease has not been shown to help people live longer, and it exposes them to side effects. Treatment starts when there are symptoms, falling blood counts, bulky or painful lymph nodes, or rapid rise in lymphocytes.
Current first-line options include:
- BTK inhibitors such as ibrutinib, acalabrutinib, and zanubrutinib, taken by mouth continuously.
- BCL2 inhibitor venetoclax, usually combined with an anti-CD20 antibody such as obinutuzumab, given for a fixed duration.
- Chemoimmunotherapy (for example, fludarabine, cyclophosphamide, and rituximab), now used far less and mostly reserved for selected fit patients with favorable genetics.
For relapsed disease, options include switching drug class, CAR T-cell therapy, and, rarely, allogeneic stem cell transplant for younger patients with high-risk disease. Supportive care matters too: vaccinations, prompt treatment of infections, and sometimes antibody replacement. See our leukemia guide for how CLL compares with other types.
Survival Rates and Outlook
CLL has one of the more favorable outlooks among leukemias. Many people with early-stage disease live for many years, some without ever needing treatment, and targeted therapies have improved results for those who do.
Outlook varies widely, though. Factors linked to a better prognosis include early stage, mutated IGHV, and absence of del(17p) or TP53 mutation. Advanced stage, TP53 abnormalities, and unmutated IGHV point to a more active disease. Doctors often combine these into a prognostic score to guide planning. Statistics describe groups, not individuals, and our article on the leukemia CLL survival rate explains how to interpret these numbers.
Frequently Asked Questions
Is chronic lymphocytic leukemia curable?
For most people, CLL is not considered curable with standard drugs, but it is highly treatable and often controlled for many years. Allogeneic stem cell transplant can be curative but carries significant risk, so it is reserved for selected patients. Many people live with CLL as a chronic condition.
Why am I not being treated right away?
Early, symptom-free CLL does not benefit from immediate treatment, so monitoring is the standard approach. Your doctor checks your blood counts and exam regularly. Treatment starts when specific criteria are met.
Is CLL hereditary?
CLL is not directly inherited, but it clusters in some families. First-degree relatives have a higher risk than the general population, although most relatives never develop it. Routine screening of family members is not usually recommended.
What infections should I watch for with CLL?
CLL weakens the immune system, so chest infections, shingles, and skin infections are more common. Report any fever promptly. Keep vaccinations up to date, but avoid live vaccines unless your hematologist approves.
